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Aim However, to emphasise this recommendation, it is 
valuable to interrogate the evidence for maintaining ADT 
in different clinical situations.
Outcome This statement, reflecting the views of the 
authors, provides a discussion of this evidence and the 
rationale behind the recommendation that ADT should be 
continued in CRPC.
Keywords Castrate-resistant prostate cancer · 
Individualised management · Backbone androgen 
deprivation therapy
Introduction
The European Association of Urology (EAU) guideline 
clearly states that when castrate-resistant prostate cancer 
(CRPC) develops, androgen deprivation therapy (ADT) 
should be continued indefinitely; this recommendation 
applies to metastatic CRPC (mCRPC) and non-metastatic 
CRPC (nmCRPC) [1]. Other guidance, such as that from 
the American Urological Association (AUA) [2] and the 
National Comprehensive Cancer Network (NCCN) [3], 
likewise mention the need to maintain ADT when CRPC 
develops. Gonadotropin-releasing hormone (GnRH) ago-
nist treatment is considered the mainstay of ADT, and 
should therefore be continued when men receiving ADT 
develop CRPC.
However, there appears to be a risk that the need to con-
tinue ADT may be overlooked by some practitioners. This 
aspect of the guidelines is sometimes not mentioned in sub-
sequent discussions. Furthermore, although randomised 
controlled trials of the many newer agents for mCRPC, 
including abiraterone, enzalutamide, sipuleucel-T, radium 
223 and cabazitaxel [4–10], all had continuation of ADT 
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and mainstay of castration levels of testosterone (<50 ng/dl) 
as an inclusion criterion, the fact that these agents are being 
used in combination with ADT is not emphasised.
Lowering testosterone levels is associated with improved 
survival in prostate cancer [11], and this underlines the 
need to maintain androgen deprivation in patients. This 
often-quoted study showed that survival was significantly 
greater if serum testosterone levels were <20 ng/dl than if 
they were 20–50 ng/dl, and survival was worst if serum 
testosterone was >50 ng/dl—however, only 73 patients 
with non-metastatic prostate cancer were included in this 
analysis [11]. In metastatic disease, while hormonal treat-
ment improves symptoms, there is no conclusive prospec-
tive evidence that lowering testosterone levels improves life 
expectancy [12].
Likewise, when chemotherapy is initiated in CRPC 
patients, the EAU recommends continuing the backbone 
ADT [1]. This guideline is based upon a single study of 
androgen priming in a small group of patients (n = 85) and 
using chemotherapy regimens that are now outdated [13]. 
Therefore, this recommendation is also worthy of scrutiny.
However, it is becoming clear that within the prostate 
and prostate tumour microenvironment androgen activity 
continues even when serum testosterone levels are sup-
pressed by ADT [14], and intracrine androgen synthesis is 
sufficient to activate androgen receptor target genes [15]. 
Adaptive alterations include alternative androgen synthesis 
pathways, and androgen receptor overexpression, muta-
tion and splice variations [16]. Furthermore, many mecha-
nisms that may confer castration resistance still require, or 
are enhanced by, the presence of androgens or androgen 
receptor ligands. Together these observations suggest that 
treatment combinations that include ADT and suppress 
intracrine and systemic androgen contributions are required 
in CRPC.
In December 2013, a group of experts (the authors of this 
paper) met to explore the evidence and rationale for con-
tinuing ADT in CRPC when other treatments are initiated. 
The aim is to provide clear statements on this issue in this 
manuscript. Before the meeting, participants were assigned 
to specific topics and conducted PUBMED searches on the 
recent literature on these topics. Assigned participants pre-
sented on these topics during the meeting, and all partici-
pants then developed the recommendations and contents of 
this paper based on all the reports presented at the meeting. 
As such, the contents of this paper represent the conclusions 
of the authors only. References in the text have been assessed 
according to their level of scientific evidence (Table 1), and 
recommendations have been graded according to the Oxford 
Centre for Evidence-based Medicine Levels of Evidence as 
used in the EAU guidelines (Table 2) [1, 17]. 
The rationale for ADT use with abiraterone
Abiraterone selectively inhibits the enzyme 17 
α-hydroxylase/C17, 20-lyase (CYP17) and thus inhibits 
androgen biosynthesis [18]. In CRPC, abiraterone acetate 
has been shown to achieve sustained suppression of testos-
terone in blood and bone marrow aspirate to <pg/ml lev-
els, when added to continuing backbone ADT [19]. Abira-
terone also has direct activity on reducing the expression 
of the androgen receptor gene [20]. Therefore, the need to 
eliminate as many parts of the androgen receptor signalling 
pathway as possible provides a rationale for combining abi-
raterone with ADT.
Table 1  Level of evidence
Level Type of evidence
1a Evidence obtained from meta-analysis of randomised trials
1b Evidence obtained from at least one randomised trial
2a Evidence obtained from one well-designed controlled study without randomisation
2b Evidence obtained from at least one other type of well-designed quasi-experimental study
3 Evidence obtained from well-designed non-experimental studies, such as comparative studies, correlation studies and case reports
4 Evidence obtained from expert committee reports or opinions or clinical experience of respected authorities
Table 2  Grade of recommendation
Grade Nature of recommendations
A Based on clinical studies of good quality and consistency that addressed the specific recommendations, including at least one  
randomised trial
B Based on well-conducted clinical studies, but without randomised clinical trials
C Made despite the absence of directly applicable clinical studies of good quality
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Crucially, experimental evidence suggests that the tes-
tosterone suppression achieved by abiraterone monotherapy 
is not sustained in non-castrated men and is overcome by a 
subsequent twofold–threefold surge in luteinising hormone 
(LH) levels [21] [level of evidence (LoE): 2b]. Conversely, 
the addition of abiraterone to backbone ADT results in sus-
tained decreases in testosterone and adrenal steroid concen-
trations [22, 23]. Although the pharmacokinetic study of 
O’Donnell et al. [21] assessed a small number of men, it 
does suggest a need to maintain castrate levels of testoster-
one with ADT when initiating abiraterone therapy.
This rationale has been used in phase III trials of abira-
terone. The efficacy of abiraterone (plus prednisolone) was 
demonstrated in two pivotal trials in patients with mCRPC; 
in one study, abiraterone was used before chemotherapy, 
and in one study, it was used after chemotherapy [4, 5] 
(LoE: 1b). Importantly, castration levels of testosterone 
were maintained in both these studies with the continuation 
of ADT.
To date, however, there have been no clinical trials com-
paring abiraterone (plus prednisolone) monotherapy with 
abiraterone plus ADT to confirm the need for continued 
ADT when initiating abiraterone therapy in patients with 
mCRPC. The planned German multicentre trial SPARE 
will investigate the impact of continuing ADT when initi-
ating abiraterone. This study (German Association of Uro-
logical Oncology trial number AUO 67/11) will investigate 
abiraterone monotherapy (plus prednisolone) versus abira-
terone plus ADT (plus prednisolone) in 70 men with chem-
otherapy-naïve mCRPC (Fig. 1). Preliminary results of 
this study may be available in 2016, and these are eagerly 
awaited as they will provide the first prospective insight on 
the potential efficacy advantages of maintaining ADT when 
abiraterone treatment is initiated in mCRPC.
Another concept that could be considered is whether abira-
terone could be used before CRPC develops, either as a mon-
otherapy alternative to ADT or in combination with ADT. A 
Abiraterone 1000 mg/d 
Prednisone 2 x 5 mg/d 
Ongoing GnRH agonist 
Abiraterone 1000 mg/d 
Prednisone 2 x 5mg/d 
Randomisation 1:1 
Primary endpoint:  Radiological - free survival (rPFS)
Secondary endpoint: PSA-response, PSA-progression free survival, 
    toxicity 
Progressive 
chemotherapy naive  
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number of ongoing trials are investigating this (Table 3). Data 
are available from one of these trials comparing abirater-
one + prednisone + leuprolide with leuprolide alone in men 
with localised high-risk prostate cancer, and these suggest 
that testosterone suppression within prostate tissue is superior 
with the combination treatment but dihydrotestosterone levels 
in prostate tissue are lower with ADT alone. Prostate-specific 
antigen (PSA) response was significantly higher in the com-
bination treatment arm after 12 weeks. Such studies on earlier 
treatment with ADT and abiraterone combination may also 
provide important information on the potential risk that ear-
lier and more aggressive treatment could accelerate the time 
to CRPC development (or increase metabolic side effects). 
Patient selection (of those with more aggressive disease) will 
be important for the future of such aggressive treatment regi-
mens, but better prognostic markers may be needed to make 
such patient selection possible.
Of all the ongoing studies of abiraterone with or without 
ADT, clearly the SPARE study will provide some valuable 
insight into the need to maintain a backbone of ADT when 
initiating abiraterone therapy in mCRPC. Until these data 
are available, and with all phase III trial data of abiraterone 
having ongoing ADT as an essential inclusion criterion, 
ADT plus abiraterone may be considered the standard of 
care in many men with asymptomatic or mildly sympto-
matic mCRPC (Grade B recommendation).
Interestingly, there are no published data assessing abi-
raterone (with or without ADT) in patients with non-met-
astatic CRPC (nmCRPC). More data on the use of newer 
agents for the treatment of nmCRPC are needed.
The rationale for ADT use with enzalutamide
Androgen receptor signalling persists during castration, and 
several mechanisms, even in individual patients (through 
clonal heterogeneity), may explain this persistence [24]. 
Addition of androgen receptor blockers to ADT may there-
fore help achieve more complete androgen blockade.
The androgen receptor blocker bicalutamide has been used 
for many years in combination with ADT to achieve com-
plete androgen blockade. However, in advanced metastatic 
prostate cancer, monotherapy with bicalutamide was inferior 
to ADT in prolonging overall survival (OS) [25] (LoE: 1b). 
Bicalutamide monotherapy also resulted in a high frequency 
of gynaecomastia (approximately 70 % of patients) [26], but 
this frequency reduced when combined with ADT (LoE: 1b). 
Bicalutamide may also function as an androgen receptor ago-
nist when androgen receptors are overexpressed (which may 
occur in up to 30 % of CRPC tumours) [27–29], with certain 
mutations of the androgen receptor [30] or in the setting of 
inflammation [31, 32].
Enzalutamide is a novel androgen receptor blocker that 
inhibits nuclear translocation of androgen receptors by 
localising the nuclear N-terminal of the androgen receptor 
to the cytoplasm [33]. Enzalutamide binds to the androgen 
receptor with eightfold higher affinity than bicalutamide 
[34]. With the development of enzalutamide, it is impor-
tant to ask whether there is any clinical difference between 
enzalutamide and bicalutamide and whether this influences 
the need to combine enzalutamide treatment with ADT.
Unlike bicalutamide, enzalutamide has no known agonist 
activity, and it is thought that bicalutamide resistance does 
not exclude subsequent enzalutamide use [34]. In addition, 
a recent report has assessed enzalutamide monotherapy in 
hormone-naive men with prostate cancer [35]. This initial 
report of enzalutamide monotherapy in 67 patients suggested 
a lower frequency of gynaecomastia (36 %) than previously 
reported with bicalutamide monotherapy. Furthermore, PSA 
declines were of a similar magnitude to those achieved by 
ADT but adverse events were frequent and testosterone lev-
els increased [35] (LoE: 2a). Therefore, more data are needed 
to determine whether the combination of enzalutamide with 
ADT has a favourable efficacy and safety profile for the treat-
ment of CRPC compared with enzalutamide monotherapy.
In the meantime, as with abiraterone, pivotal trials of 
enzalutamide in men with CRPC included the need for 
castration maintenance with ADT [6, 7], and these studies 
have shown that this combination improved OS when used 
before chemotherapy and after chemotherapy (LoE: 1b). 
Furthermore, there was a low frequency of seizure as a side 
effect of enzalutamide [7] suggesting that the safety profile 
of enzalutamide does not represent a problem when com-
bining it with ADT (LoE: 1b).
Table 4  Ongoing studies investigating enzalutamide and ADT
Trial identifier Overview of design Patients Expected results
NCRN322 (TERRAIN) ADT + enzalutamide versus ADT +  
bicalutamide
370 men with mCRPC December 2014
NCT01547299 Enzalutamide monotherapy versus  
enzalutamide + leuprolide + dutasteride
As neoadjuvant treatment in approximately 
50 men with localised prostate cancer  
who are undergoing RP
Trial completed in 2013
NCT02003924 (PROSPER) ADT + enzalutamide versus ADT alone Approximately 1,560 men with nmCRPC 2017
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Ongoing clinical studies may provide some clues to the 
need for backbone ADT when initiating enzalutamide in 
patients with CRPC (Table 4). However, there are no tri-
als with enzalutamide that are equivalent to the SPARE 
study with abiraterone, which directly compare enzaluta-
mide monotherapy with enzalutamide combined with ADT 
in men with CRPC. In the absence of any such data or the 
prospect of such data being published, the potential adverse 
event of gynaecomastia with enzalutamide monotherapy, 
and with all phase III trial data of enzalutamide having 
ongoing ADT as an essential inclusion criterion, backbone 
ADT should be continued when initiating enzalutamide. 
Potential long-term safety considerations of combining 
ADT with enzalutamide need to be assessed further.
ADT during chemotherapy
EAU guidelines state that ADT with GnRH analogues 
should be continued when giving mCRPC patients chemo-
therapy [1]. This is based upon the data of a single study 
[13], in which 85 men with CRPC refractory to orchiec-
tomy receiving a now outdated chemotherapy regimen (and 
thus, the survival time was shorter than would be expected 
today) had worse median survival if they were androgen 
primed (10 vs. 15 months if not primed) (LoE: 3).
The rationale for continuing ADT when starting chem-
otherapy in mCRPC is that stopping ADT may lead to 
renewed release of testosterone and stimulation of the 
remaining androgen-sensitive elements of the tumour. 
Conversely, approximately 50 % of men receiving ADT 
in the long-term remain castrated for 2.5 years after stop-
ping ADT [36] (LoE: 3), and stopping ADT may re-induce 
hormone sensitivity [37] (LoE: 2b). These conflicting 
viewpoints are difficult to prove as there is a lack of well-
designed prospective trials exploring this issue, and retro-
spective data are conflicting [38–40]. There is no strong 
evidence that the combination of ADT with chemotherapy 
causes harm but there is also no strong evidence of benefit.
Recent pivotal trials of chemotherapy in prostate can-
cer have stipulated that ADT should be continued when 
chemotherapy was initiated [10, 41] (LoE: 1b), and guide-
lines all recommend continuation of ADT when initiating 
chemotherapy [1, 42]. Furthermore, the ChemoHormonal 
therapy versus Androgen Ablation Randomized Trial for 
Extensive Disease in prostate cancer (CHAARTED; Clini-
calTrials.gov identifiers: NCT00309985) recently reported 
that in hormone-naïve men with metastatic prostate can-
cer, OS was improved and metastatic load was decreased 
when treatment was initiated with ADT plus chemother-
apy versus ADT alone (http://www.nih.gov/news/health/
dec2013/nci-05.htm). Conversely, an open-label phase III 
trial showed no benefit of adding chemotherapy to ADT as 
first-line treatment compared with ADT alone in hormone-
sensitive men with metastatic prostate cancer [43] (LoE: 
1b). These conflicting results do not help clarify the value 
of maintaining ADT when initiating chemotherapy in men 
with mCRPC, and care should be taken if trying to extrapo-
late these data to the mCRPC setting.
An alternative approach to that currently recommended 
may be to stop ADT when starting chemotherapy and then 
monitor testosterone levels; restarting ADT when testoster-
one levels go above the threshold for castration. Two ongo-
ing studies (ClinicalTrials.gov identifiers: NCT01487902 and 
NCT01224405) are investigating the possible advantage of 
maintaining ADT during chemotherapy. One of these stud-
ies (NCT01487902) that is comparing docetaxel plus pred-
nisolone with docetaxel plus prednisolone and leuprolide in 
approximately 90 men with CRPC was due for completion 
in October 2013, and results may therefore be available soon. 
Until these results are available ADT should be continued 
when chemotherapy is initiated in mCRPC in daily practice.
Discussion
All clinical trials of newer agents (and recent trials of chem-
otherapy agents) in mCRPC include patients who main-
tain castrate levels of testosterone, and so clinical practice 
should adhere to this principle of continuing ADT when 
initiating abiraterone, enzalutamide or chemotherapy. Like-
wise, experimental agents that are in advanced stages of 
clinical development for treatment of CRPC are all being 
assessed in patients who maintain their castration status with 
ADT, and so this recommendation is likely to apply to other 
agents that may be registered in the next few years. How-
ever, not only are more prospective data needed to assess 
the importance of backbone ADT in CRPC, but also reliable 
prognostic and predictive biomarkers are urgently needed to 
individualise treatment with newer agents, their combina-
tion with ADT, and the optimum treatment sequences.
Another consideration is that ADT as the standard of 
care may be moving earlier in the disease continuum, and 
the availability of newer agents means that optimum treat-
ment sequences that include ADT need to be ascertained in 
CRPC and in less advanced prostate cancer.
Finally, more trial data are urgently needed on the man-
agement of patients with nmCRPC; EAU definition of CRPC 
does not require the presence of metastases but it is possible 
that all patients with CRPC have metastatic disease and those 
classified as having nmCRPC have metastases that cannot be 
detected with current techniques. Irrespective of this, very 
few studies have included appreciable numbers of patients 
that would currently be considered nmCRPC. In practice, the 
lack of data means that maintaining ADT in these nmCRPC 
patients is the recommended treatment option—it is unclear 
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if bone-targeted treatment is also useful in this setting. For 
example, in the Zometa European Study (ZEUS), zoledronic 
acid did not prevent bone metastases or improve OS in M0 
patients (http://www.medscape.com/viewarticle/781457). 
Whereas, the 147 trial suggested that denosumab may delay 
the onset of skeletal-related events (which included bone 
metastases) in patients with CRPC, but the adverse event 
profile was not favourable [44] (LoE: 1b).
Panel recommendations
•	 The emergence of several agents for the management of 
CRPC has the potential to prolong and enhance the life 
of men with this disease. As data emerge on these new 
agents and on improving biomarkers, a more individual-
ised approach to the use of these newer agents and their 
combination with ADT will optimise management fur-
ther (Grade C recommendation).
•	 As all randomised prospective data for abiraterone use 
in CRPC include the continuation of backbone ADT, 
and based upon the findings of O’Donnell et al. [21] that 
suggested abiraterone monotherapy does not sustain 
testosterone suppression in non-castrated men, ADT 
should be maintained in men with CRPC when they ini-
tiate abiraterone treatment (Grade B recommendation).
•	 All phase III trial data of enzalutamide in CRPC include 
the continuation of backbone ADT. This combined with 
the potential adverse event of gynaecomastia with enza-
lutamide monotherapy suggest that ADT should be con-
tinued when initiating enzalutamide in men with CRPC 
(Grade B recommendation).
•	 When initiating chemotherapy in CRPC, data on the 
benefits of continuing ADT are conflicting. However, in 
the absence of any clear evidence of harm and because 
prospective phase III trial data maintain ADT, it is recom-
mended that backbone ADT is maintained when chemo-
therapy is initiated in CRPC (Grade B recommendation).
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